bioRxiv Science⌕ Search

bioRxiv · 10.1101/2023.07.27.550860

A Subset of HIV 1 Controllers Lack Cortical Actin Disruption Indicative of ARP2/3 Inhibition.

Abstract

A small fraction of people living with HIV-1 suppress viral replication naturally and exhibit delayed or absent disease progression without antiretroviral therapy, yet the underlying mechanisms of viral control remain elusive. Despite the known role of HIV-1 in disrupting the actin cytoskeleton and altering cell migration and morphology within tissues, the molecular underpinnings that link viral actin disruption to disease progression have yet been linked to disease progression. We have previously shown through ultrastructural and time-lapse imaging that HIV-1 mediated actin disruption mirrors ARP2/3 inhibition within primary CD4+ T cells of normal progressors and uninfected controls. Infected CD4+ T cells from these two cohorts routinely exhibit two unique phenotypes when migrating. The first morphological difference is a sharp elongated and pointed lamellipodial tip, "Rhino" phenotype, distinct from the broad leading edge of uninfected cells. The second morphological difference is a non-apoptotic polarized blebbing at the lamellipodia of infected cells. These two pathological morphologies can be recapitulated in uninfected cells with chemical inhibitors of the ARP2/3 complex and are temporally linked based on the differentiation status of the T cell. These effects are dampened, but not totally eradicated, in the absence of the HIV-1 Nef protein. In contrast to normal progressors, infected cells from two out of the three HIV-1 controllers tested in this study did not exhibit these cellular pathologies. The profound impact of ARP2/3 inhibition on immunopathogenesis within genetic and infectious diseases provides context into how HIV-1 may cause cellular and systemic immune dysfunction in normal progressors. The mechanically destabilized cellular cortex may also provide a selective protection for viral genome-intact and long-lived defective reservoirs from cell-mediated killing by host CD8+ T cells and NK cells. This mechanical instability is absent in some HIV-1 controllers. Restoring ARP2/3 function and cortical actin integrity in people living with HIV-1 infection is a new avenue of investigation to eradicate HIV-1 infected cells from the body.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

O'Brien, R. L. F., Kovacs, C.. 2023-07-29. A Subset of HIV 1 Controllers Lack Cortical Actin Disruption Indicative of ARP2/3 Inhibition.. https://doi.org/10.1101/2023.07.27.550860

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Ksp37 is a rapidly mobilized NK cell secretory protein that engages FGF2

A key feature of natural killer (NK) cells is their preloaded arsenal of effector molecules, allowing them to rapidly respond upon activation. In this study, we characterized a previously unexplored secretory protein, termed killer-specific secretory protein of 37 kDa (Ksp37), which is highly abundant in differentiated CD56dim NK cells. Ksp37 is rapidly secreted in a dose-dependent and JAK-1 dependent manner upon low levels of cytokine stimulation, making it a sensitive readout for NK cell activation. Following secretion, intracellular levels were rapidly replenished, preserving responsiveness to subsequent cytokine stimulation. We found that Ksp37 is stored in polarized intracellular compartments distinct from those containing canonical cytotoxic effector molecules, including granzyme B and perforin, which require stronger stimulation for release. Lastly, we identified Ksp37 as a novel binding partner of fibroblast growth factor 2 (FGF2). This opens new avenues of exploration for the role of NK cells in remodeling their extracellular environment by modulating the FGF2-FGFR1 axis, which plays a key role in tumor growth, angiogenesis and tissue repair.

immunology↗

ACE-engineered human iPSC-derived neutrophils enhance host defense against multidrug-resistant bacterial infections

Severe neutropenia predisposes patients to life-threatening infections, while donor-dependent granulocyte transfusions are limited by availability and variable cell quality. Here, we engineered human induced pluripotent stem cells (iPSCs) to constitutively or inducibly express angiotensin-converting enzyme (ACE) and differentiated them into functional ACE-engineered neutrophils (ACE-iNeu). ACE expression enhanced granulocytic maturation, reactive oxygen species generation, inflammatory cytokine production, and antimicrobial signaling. ACE-iNeu exhibited enhanced bactericidal activity against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. Following adoptive transfer into neutropenic mice, ACE-iNeu significantly reduced circulating and tissue bacterial burdens. Integrated metabolomic and transcriptomic analyses revealed ACE-associated alterations in adenine nucleotide abundance and developmental and inflammatory pathways. Together, these findings establish ACE engineering as a strategy to enhance the production and antimicrobial function of human iPSC-derived neutrophils and support further preclinical development of engineered granulocyte therapies for severe drug-resistant infections.

immunology↗

Tetravalent dengue mRNA vaccination orchestrates balanced four-serotype immunity with durable memory and protection in mice.

An effective dengue vaccine must establish durable immunity across four dengue virus (DENV) serotypes, evade antibody-dependent enhancement (ADE), and overcome immune imprinting from prior exposure. Here, we developed TetprM-E mRNA-LNP, a tetravalent vaccine comprising LNP-formulated nucleoside-modified mRNAs encoding DENV1-4 precursor membrane-envelope (prM-E) antigens, and evaluated its immunogenicity, durability, protection and breath across serotype-specific immune backgrounds. Three immunization strategies elicited neutralizing titers greater than 1:1500 against each serotype. Passive transfer of immune sera conferred 100% survival and reduced viremia after lethal DENV2 challenge in immunocompromised mice. Vaccination induced DENV envelope (env)-specific CD8+T cells and CD4-dependent germinal-center responses. DENV env-binding antibodies persisted for 34 weeks alongside DENV env-specific memory B cells. Vaccine-elicited sera showed no measurable in vitro ADE. Although monovalent priming initially biased antibody responses, TetprM-E mRNA-LNP vaccination broadened neutralization across DENV1-4 regardless of priming serotype. Together, TetprM-E mRNA-LNP elicits broad, durable, and protective immunity despite serologic constraints from pre-existing immunity.

immunology↗